Compare Public Storage (PSA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Vertex Pharmaceuticals Incorporated — how do they compare? Public Storage trades at $311.4 (market cap $54.39B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× Public Storage's market cap, and Public Storage pays a 3.87% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PSA | VRTX | |
|---|---|---|
Market Cap | $54.39B | $122.33B |
Sector | Real Estate | Health |
52-Week High | $329.64 | $529.59 |
52-Week Low | $258.44 | $366.54 |
Enterprise Value | $68.63B | $117.07B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $309.75, down 2.61% on the day, with a bearish technical signal but strong fundamentals including a 39.16% net income margin and consistent earnings beats. Recent developments include the pending acquisition of National Storage Affiliates and a $3.00 dividend payment scheduled for June 30, 2026. The stock is near its 52-week high of $331.00, reflecting investor confidence in its growth trajectory and sector leadership.
The outlook remains positive due to robust profitability, strategic expansions into Canada, and analyst consensus pointing to a $332.25 price target. Key risks include integration challenges from acquisitions and interest rate sensitivity. With 65.72% of analysts rating it Hold, the stock offers steady income potential but requires monitoring of execution risks and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
